Filtravate was formed in 2020 to commercialize advanced antifouling filtration membrane technology to meet growing and unmet needs in the multibillion-dollar bioprocessing membrane market. The technology is exclusively licensed from New Mexico State University. Filtravate is developing next generation membranes to enable continuous bioprocessing.

The Problem: Membrane fouling is a byproduct of filtration processes where particles are deposited on or in a membrane during filtration. This deposition of particles can both block the pores through the membrane and alter the surface properties of the membrane, both of which degrade the membrane’s performance. Membrane fouling decreases the amount of product that can be filtered and decreases the quality of the final product. In addition to adding significant costs to manufacturing, membrane fouling is a major obstacle to the widespread development of continuous bioprocessing operations in biomanufacturing and pharmaceutical production.

The Solution: Filtravate has a patent-pending process to fabricate membranes that resist membrane fouling and improve filtration performance. Filtravate’s membrane fabrication technology has demonstrated vastly superior antifouling performance compared to the commercially available membranes, and with lower manufacturing cost. In addition to stable flux during filtration and decreased biofouling, Filtravate’s membrane technology can be customized to optimize membranes to meet specific filtration needs. Further, the pore size is highly controllable depending on the application needs. For example, in viral filtration, Filtravate’s pore size is designed to be around 14 to 20 nm, ideal for parvovirus filtration in monoclonal antibody (mAb) processing.

Market Opportunity: The biomanufacturing pharmaceutical membrane filtration market, currently valued at $5.1 billion, is projected to grow at a CAGR of 11.0% to reach $8.6 billion by 2024. One of the primary target applications for Filtravate’s technology is monoclonal antibody (mAb) bioprocess. More specifically, the single use mAb facilities. We are focusing our first membrane product (FIL-V1) on the applications for the viral clearance downstream processes in the single-use system.  The global single-use bioreactors market is projected to reach USD 8.8 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 21.1% during the forecast period. The mAb market, as the driving force for mAb manufacturing, has seen 50% growth from 2013 to 2019, with global sales around $163 billion, which accounts for 70% of the total sales for all biopharmaceutical products.


Investment information is restricted to VIN members. Become a member to view investment opportunities. 

Thank you for your investment interest. A VIC Investor Network representative will contact you within 5 business days with additional information regarding investment in the company you have selected.